Skip to main content
Premium Trial:

Request an Annual Quote

Personalis: Karin Eastham

Menlo Park, California-based Personalis has appointed Karin Eastham as independent director to its board of directors. Eastham currently serves as board member for Geron, Veracyte, and Nektar Therapeutics. Prior to Personalis, Eastham served as executive VP and chief operating officer, as well as a member of the board of trustees, at the Burnham Institute for Medical Research from 2004 to her retirement in 2008. She previously served on the boards of Illumina, MorphoSys, Trius Therapeutics, Amylin Pharmacueticals, Genoptix, Tercica, and SGX Pharmaceuticals. 

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.